The Food and Drug Administration released guidance in July outlining recommendations for sponsors developing psychedelic drugs for the treatment of medical conditions, including psychiatric disorders and substance use disorders. The guidance addresses chemistry, manufacturing, nonclinical testing, abuse potential and clinical…
Interventional Psychiatry
Compass Pathways reported that 39% of patients in the 25 milligrams arm of a phase 3 trial for highly chronic treatment-resistant depression achieved a clinically meaningful response after two doses of its synthetic, proprietary formulation of psilocybin and maintained that…
Ketamine clinics have grown from fewer than 100 nationwide in 2015 to more than 1,500 by 2024, part of a market estimated at roughly $3.4 billion to $3.8 billion. The drug is a dissociative anesthetic that distorts perceptions of sight…
Health systems are investing in interventional psychiatry programs as demand for treatment-resistant depression therapies rises and payer policies evolve. In 2021, an estimated 8.9 million U.S. adults were treated for major depressive disorder each year, and about 2.8 million —…